Latest Product Monograph

June 15, 2017

Victoza® for use in monotherapy

Victoza® can be used in combination with diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance.

In a study, 746 patients with type 2 diabetes were randomized to Victoza® 1.2 mg (n=251), Victoza® 1.8 mg (n=247), or glimepiride 8 mg (n=248) in the 52-week, multicentre, double-blind, double-dummy, randomized, parallel, active-controlled LEAD 3 trial. These patients had previously been treated with diet/exercise (n=272) or not more than half-maximal OAD monotherapy (n=474) for at least 2 months.

At 52 weeks, patients on Victoza® 1.8 mg saw mean A1C reductions of 1.1% (p<0.05) and those on Victoza® 1.2 mg saw a mean reduction on 0.8% (p<0.0001) versus 0.5% for glimepiride 8 mg (all baseline 8.2%).

The secondary endpoint of mean weight change showed a 2.5 kg reduction with Victoza® 1.8 mg (baseline 92.6 kg), a 2.1 kg reduction with Victoza® 1.2 mg (baseline 92.1 kg), and a 1.1 kg increase in weight with glimepiride 8 mg (baseline 93.3 kg).

The percentage of patients achieving an A1C target of <7% was 51% with Victoza® 1.8 mg, 43% with Victoza® 1.2 mg, and 28% with glimepiride 8 mg.1

Latest Product Monograph

June 15, 2017

Victoza® can be used without dose adjustment in patients with hepatic insufficiency1

There is limited clinical experience in patients with mild, moderate or severe hepatic insufficiency. No dose adjustment is required for patients with hepatic insufficiency.1

innoviCares

January 26, 2017

Victoza® added to innoviCares program

1.5 million Canadians already use the innoviCares payment assistance card to save on prescription medications.

All your patient needs do is to present their innoviCares card and Victoza® prescription at their local pharmacy. The innoviCares card will automatically cover a portion of the drug acquisition cost of their Victoza® prescription.

Guidelines update

November 30, 2016

The CDA has updated its 2013 guidelines

The Canadian Diabetes Association has created an update to the 2013 guidelines this past November.

See all the updates and download the Quick Reference Guide at the CDA website.

Study published

September 8, 2016

See below for results from the LIRA-SWITCH study

The LIRA-SWITCH trial was a phase 4, 26-week, randomized, multicentre, parallel-group, double-blind, double-dummy, active-controlled trial studying patients 18 years or over with a BMI of 20 kg/m2 or over and A1C between 7.5% and 9.5% who were inadequately controlled on stable sitagliptin and metformin.

At 26 weeks, patients who were inadequately controlled on sitagliptin and metformin achieved statistically significant A1C reductions on a regimen of Victoza® and metformin versus continuing sitagliptin and metformin (-1.1% for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. -0.54% for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001).5‡

In secondary endpoints, also in patients inadequately controlled on sitagliptin and metformin:
Victoza® and metformin showed statistically significant weight reductions versus continuing sitagliptin and metformin (-3.3 kg for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. -1.6 kg for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001); and Victoza® and metformin showed a statistically significant proportion of patients achieved target A1C <7% versus continuing sitagliptin and metformin (50.6% for Victoza® 1.8 mg + MET + oral placebo, n=204 vs. 26.9% for sitagliptin 100 mg + MET + placebo injection, n=203; p<0.0001).5‡

‡Baseline values for Victoza® + MET/sitagliptin + MET arm: A1C (%): 8.3/8.2; body weight (kg): 88.9/91.2.

Latest Product Monograph

April 19, 2016

Victoza® can be used without dose adjustment in patients with moderate or mild renal insufficiency1

There is no dose adjustment required in moderate renal patients (creatinine clearance 30-59 mL/min) or mild renal patients (60-90 mL/min).

There is very limited or no clinical experience with Victoza® in patients with severe renal insufficiency (<30 mL/min), including end-stage renal disease; use of Victoza® in these patients is not recommended.1

This April 2016 Product Monograph update remains unchanged in the latest June 2017 Product Monograph update.

Victoza® is indicated for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with:

  • Metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.

  • Metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control.

  • Metformin and a basal insulin, when diet and exercise plus dual therapy with Victoza® and metformin do not achieve adequate glycemic control.

Click here for information on:

  • Contraindications in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2) and pregnant or breast-feeding women

  • A serious warning on risk of thyroid C-cell tumours including medullary thyroid carcinoma in humans

  • Other relevant warnings and precautions relating to risk of CV effects (increased heart rate, PR interval prolongation), treatment of diabetic ketoacidosis, intravenous or intramuscular administration, hypoglycemia in combination with a sulfonylurea, individual pen use, pancreatitis, recent MI, unstable angina and congestive heart failure, hepatic and renal impairment, gastrointestinal disease, hypersensitivity

  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

See Product Monograph for complete dosing and administration. The Product Monograph is also available by calling us at 1-800-465-4334.

Ask Med Info

If you have a specific question about Victoza®, please email our Medical Information team using the form below. We will get back to you as soon as possible.



Resources

The latest Victoza® Product Monograph dated June 15, 20171.

The new Victoza® VIP program is a resource for you to use with your patients during consultations, including how-to videos and other resources to get them started.

TRUST in our real-world experience.

#1 GLP-1 receptor agonist dispensed, Canada and worldwide2,3

>1,130,000 patients worldwide have been prescribed Victoza® 3